2. Apoptosis Cell Cycle/DNA Damage PI3K/Akt/mTOR
  3. Apoptosis PERK mTOR
  4. Dinutuximab

Dinutuximab  (Synonyms: APN-311)

Cat. No.: HY-P9933 Purity: ≥99.0%
SDS
COA
Technical Support

Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer.

For research use only. We do not sell to patients.

CAS No. : 1363687-32-4

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Dinutuximab Featured Recommendations:

Dinutuximab Related Antibodies

Top Publications Citing Use of Products

View All mTOR Isoform Specific Products:

View All Isoforms
mTOR mTORC1 mTORC2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer[1][2][3].

IC50 & Target

GD2[1]
In Vitro

Dinutuximab (0-5000 ng/mL; 0-12 days) can inhibit the adhesion, migration, and mammosphere formation, induce apoptosis of breast cancer cells MDA-MB-231, and inhibit the phosphorylation of mTOR, ERK, and 4E-BP1[1].
Dinutuximab (100 ng/mL; 6-72 h), when used in combination with in vitro-activated natural killer cells (aNK) in human neuroblastoma cell lines SH-SY5Y-Fluc, CHLA-136-Fluc, and CHLA-255-Fluc, significantly reduces the viability and invasive ability of tumor cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Dinutuximab Related Antibodies

Western Blot Analysis[1]

Cell Line: MDA-MB-231 cells
Concentration: 0, 500, 1000 and 5000 ng/mL
Incubation Time: 24 h
Result: Inhibited the levels of pmTOR, pERK and p4E-BP1.
In Vivo

Dinutuximab (15 μg; tail vein injection; twice a week; 4 weeks) has anti-tumor activity in a mouse neuroblastoma model[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NSG mice aged 6-8 weeks old treated CHLA-136-Fluc, CHLA-255-Fluc or COG-N-415x cells[2]
Dosage: 15 μg
Administration: Tail vein injection; twice a week; 4 weeks
Result: Significantly decreased the incidence and quantity of tumor cells in the liver and bone marrow and increased the survival rate of mice when combined with aNK cells.
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

145.012 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Dinutuximab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation

Purity: ≥99.0%

SDS (251 KB)

COA (232 KB) SDS-PAGE (157 KB) SEC-HPLC (96 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Dinutuximab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Dinutuximab1363687-32-4APN-311APN311APN 311ApoptosisPERKmTORProtein kinase R-like endoplasmic reticulum kinasePKR-like endoplasmic reticulum kinaseMammalian target of RapamycinMDA-MB-231neuroblastoma modelCHLA-136-FlucCHLA-255-FlucCOG-N-415xInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Dinutuximab
Cat. No.:
HY-P9933
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.